APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis

Uddin, Md. Sahab; Kabir, Md. Tanvir; Al Mamun, Abdullah; Abdel-Daim, Mohamed M.; Barreto, George E.; Ashraf, Ghulam Md

doi:10.1007/s12035-018-1237-z

Cited by 212Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis

Uddin, Md. Sahab, Kabir, Md. Tanvir, Al Mamun, Abdullah, Abdel-Daim, Mohamed M., Barreto, George E., Ashraf, Ghulam Md·2019·Molecular Neurobiology

DOI 10.1007/s12035-018-1237-z

Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD) is an immutable neurodegenerative disease featured by the two hallmark brain pathologies that are the extracellular amyloid ß (Aß) and intraneuronal tau protein. People carrying the APOE4 allele are at high risk of AD concerning the ones carrying the ε3 allele, while the ε2 allele abates risk. ApoE isoforms exert a central role in controlling the transport of brain lipid, neuronal signaling, mitochondrial function, glucose metabolism, and neuroinflammation. Regardless of widespread indispensable studies, the appropriate function of APOE in AD etiology stays ambiguous. Existing proof recommends that the disparate outcomes of ApoE isoforms on Aβ accretion and clearance have a distinct function in AD pathogenesis. ApoE-lipoproteins combine diverse cell-surface receptors to transport lipids and moreover to lipophilic Aβ peptide, that is believed to begin deadly events that generate neurodegeneration in the AD. ApoE has great influence in tau pathogenesis, tau-mediated neurodegeneration, and neuroinflammation, as well as α-synucleinopathy, lipid metabolism, and synaptic plasticity despite the presence of Aβ pathology. ApoE4 shows the deleterious effect for AD while the lack of ApoE4 is defensive. Therapeutic strategies primarily depend on APOE suggest to lessen the noxious effects of ApoE4 and reestablish the protective aptitudes of ApoE. This appraisal represents the critical interactions of APOE and AD pathology, existing facts on ApoE levels in the central nervous system (CNS), and the credible active stratagems for AD therapy by aiming ApoE. This review also highlighted utmost ApoE targeting therapeutic tactics that are crucial for controlling Alzheimer's pathogenesis.

Integrity signals

Registry

Crossref · 10.1007/s12035-018-1237-z

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

ApoE4 is highly susceptible to neuron-specific proteolysis, which generates neurotoxic fragments.
“As mentioned above, apoE4 is highly susceptible to neuron-specific proteolysis, which generates neurotoxic fragments [20, 77–79].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [77]

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1× · see citing works
“Instead, a more violent amyloid model mice known as 5xFAD [50], amyloid plaque deposition was far more in E4FAD mice, and E2/E3FAD mice have considerably higher diffuse plaques with E4FAD showing more dense plaques [51].”
Background
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · see citing works
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · see citing works
Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · see citing works
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · see citing works
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · see citing works
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722 · see citing works
MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652 · see citing works
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 1× · see citing works
“Miscellaneous Promoting cerebrovascular integrity ▪ Enhance Aβ clearance ▪ Inhibit ApoE4-facilitated BBB breakdown Cyclosporine A [168]”
Background
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · see citing works
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168 · see citing works
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · see citing works
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029 · see citing works
APP processing in Alzheimer’s disease.
Zhang, Y.-W., Thompson, R., Zhang, H., & Xu, H. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-3 · Cited by 983 · see citing works
Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912 · see citing works
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876 · see citing works
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871 · see citing works
Alzheimer's disease
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859 · see citing works
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830 · see citing works
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · see citing works
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · see citing works
Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · see citing works
Apolipoprotein E ε4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease
Kivipelto, M., Helkala, E., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645 · see citing works
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · see citing works
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587 · see citing works
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · see citing works
ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion
Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528 · see citing works
Apolipoprotein E is essential for amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., Fishman, C. E., DeLong, C. A., Piccardo, P., Petegnief, V., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15233 · Cited by 486 · see citing works
Inducible in vivo genome editing with CRISPR-Cas9
Dow, L. E., Fisher, J., O’Rourke, K. P., Muley, A., Kastenhuber, E. R., Livshits, G., Tschaharganeh, D. F., Socci, N. D., & Lowe, S. W. (2015) · Nature Biotechnology · doi:10.1038/nbt.3155 · Cited by 482 · see citing works
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474 · see citing works
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · see citing works
Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications
Uddin, M. S., Stachowiak, A., Mamun, A. A., Tzvetkov, N. T., Takeda, S., Atanasov, A. G., Bergantin, L. B., Abdel‐Daim, M. M., & Stankiewicz, A. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00004 · Cited by 440 · see citing works
Self-citation
APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., Warner, D. S., & Laskowitz, D. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306923200 · Cited by 394 · see citing works
Incidence of Dementia and Alzheimer Disease in 2 Communities
Hendrie, H. C., Ogunniyi, A. O., Hall, K. S., Baiyewu, O., Unverzagt, F. W., Gureje, O., Gao, S., Evans, R. M., Ogunseyinde, A. O., Adeyinka, A. O., et al. (2001) · JAMA · doi:10.1001/jama.285.6.739 · Cited by 393 · see citing works
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons
Huang, Y., Liu, X. Q., Wyss-Coray, T., Brecht, W. J., Sanan, D. A., & Mahley, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151254698 · Cited by 392 · see citing works
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33622 · Cited by 370 · cited 1× · see citing works
“[173] stated that ABCA1 deletion could upsurge the deposition of Aβ peptide.”
Background
ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling
Chen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368 · see citing works
Dietary ketosis enhances memory in mild cognitive impairment
Krikorian, R., Shidler, M. D., Dangelo, K. N., Couch, S. C., Benoit, S. C., & Clegg, D. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.006 · Cited by 365 · see citing works
Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · see citing works
Apolipoprotein E element 4 association with dementia in a population-based study: The Framingham Study
Myers, R. H., Schaefer, E. J., Wilson, P. W. F., D'Agostino, R., Ordovas, J. M., Espino, A., Au, R., White, R. F., Knoefel, J. E., Cobb, J. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.673 · Cited by 346 · see citing works
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 342 · see citing works
Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II)
Svennerholm, L. T., & Gottfries, C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62031039.x · Cited by 327 · see citing works
Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures
Zheng, W.-H., Bastianetto, S., Mennicken, F., Ma, W., & Kar, S. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00404-9 · Cited by 321 · see citing works
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
Chang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508254102 · Cited by 319 · see citing works
Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall
Getz, G. S., & Reardon, C. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800058-jlr200 · Cited by 319 · see citing works
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · see citing works
The Liver X Receptor Ligand T0901317 Decreases Amyloid β Production in Vitro and in a Mouse Model of Alzheimer's Disease
Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411420200 · Cited by 279 · see citing works
Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model
Fryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278 · see citing works
Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275 · see citing works
HumanAPOEIsoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274 · see citing works
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267 · see citing works
Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition
Liu, C.-C., Hu, J., Zhao, N., Wang, J., Wang, N., Cirrito, J. R., Kanekiyo, T., Holtzman, D. M., & Bu, G. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3442-16.2017 · Cited by 267 · see citing works
APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway
Sando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. O. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-9 · Cited by 261 · see citing works
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 259 · cited 1× · see citing works
“Instead, a more violent amyloid model mice known as 5xFAD [50], amyloid plaque deposition was far more in E4FAD mice, and E2/E3FAD mice have considerably higher diffuse plaques with E4FAD showing more dense plaques [51].”
Background
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 254 · see citing works
The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease
Benskey, M. J., Perez, R. G., & Manfredsson, F. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13570 · Cited by 247 · see citing works
The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.01.011 · Cited by 244 · see citing works
Genome-Wide Association Studies in Alzheimer Disease
Waring, S. C., & Rosenberg, R. N. (2008) · Archives of Neurology · doi:10.1001/archneur.65.3.329 · Cited by 238 · see citing works
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E., Boza‐Serrano, A., Brioschi, S., Castro‐Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 236 · see citing works
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers
(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetic Consortium (ADGC), Li, Z., Kapoor, M., Harari, O., Del-Aguila, J. L., Black, K., Carrell, D., Cai, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1685-y · Cited by 231 · see citing works
Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210 · see citing works
α-Synuclein Senses Lipid Packing Defects and Induces Lateral Expansion of Lipids Leading to Membrane Remodeling
Ouberai, M. M., Wang, J., Swann, M. J., Galvagnion, C., Guilliams, T., Dobson, C. M., & Welland, M. E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478297 · Cited by 206 · see citing works
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204 · see citing works
ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice*
Donkin, J. J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., Chan, J., Fan, J., Collins, J., & Wellington, C. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.108100 · Cited by 200 · see citing works
Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis
Kim, J., Jiang, H., Park, S., Eltorai, A. E. M., Stewart, F. R., Yoon, H., Basak, J. M., Finn, M. B., & Holtzman, D. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3773-11.2011 · Cited by 199 · see citing works
A new way to produce hyperketonemia: Use of ketone ester in a case of Alzheimer's disease
Newport, M. T., VanItallie, T. B., Kashiwaya, Y., King, M. T., & Veech, R. L. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.01.006 · Cited by 192 · see citing works
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190 · see citing works
Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response
Lynch, J., Morgan, D., Mance, J., Matthew, W. D., & Laskowitz, D. T. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00459-8 · Cited by 188 · see citing works
Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183 · cited 1× · see citing works
“[113] stated that old ApoE-deficient transgenic mice ex-”
Background
Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer’s disease-like pathology
Nuriel, T., Angulo, S. L., Khan, U., Ashok, A., Chen, Q., Figueroa, H. Y., Emrani, S., Liu, L., Herman, M., Barrett, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01444-0 · Cited by 181 · see citing works
Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease
Liu, C.-C., Zhao, N., Yamaguchi, Y., Cirrito, J. R., Kanekiyo, T., Holtzman, D. M., & Bu, G. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3650 · Cited by 180 · see citing works
Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
Agosta, F., Vossel, K. A., Miller, B. L., Migliaccio, R., Bonasera, S. J., Filippi, M., Boxer, A. L., Karydas, A., Possin, K. L., & Gorno-Tempini, M. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812697106 · Cited by 178 · see citing works
Correlating familial Alzheimer’s disease gene mutations with clinical phenotype
Ryan, N. S., & Rossor, M. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.92 · Cited by 176 · see citing works
Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Aβ Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice
Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., & Huang, Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0033-12.2012 · Cited by 170 · see citing works
Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167 · see citing works
Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons
Chen, H.-K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R. D., McGuire, J. G., Pleiss, M. A., Ji, Z.-S., Balestra, M. E., Walker, D. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276162 · Cited by 163 · see citing works
Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161 · see citing works
Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis
Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160 · see citing works
The role of APOE on lipid homeostasis and inflammation in normal brains
Rebeck, G. W. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075408 · Cited by 160 · see citing works
Genetic studies of human apolipoproteins
Sepehrnia, B., Kamboh, M. I., Adams-Campbell, L. L., Bunker, C. H., Nwankwo, M. U., Majumder, P. P., & Ferrell, R. E. (1989) · Human Genetics · doi:10.1007/bf00284041 · Cited by 156 · see citing works
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154 · see citing works
Liver X receptor activation restores memory in aged AD mice without reducing amyloid
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J. G., Steinbusch, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.005 · Cited by 154 · see citing works
A Synthetic Peptide Blocking the Apolipoprotein E/β-Amyloid Binding Mitigates β-Amyloid Toxicity and Fibril Formation in Vitro and Reduces β-Amyloid Plaques in Transgenic Mice
Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154 · see citing works
Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase
Harris, F. M., Brecht, W. J., Xu, Q., Mahley, R. W., & Huang, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408127200 · Cited by 151 · see citing works
Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149 · see citing works
A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145 · see citing works
Familial Alzheimer’s Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide
Hatami, A., Monjazeb, S., Milton, S. C. F., & Glabe, C. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755264 · Cited by 144 · see citing works
α-Synuclein Expression Modulates Microglial Activation Phenotype
Austin, S. A., Floden, A. M., Murphy, E. J., & Combs, C. K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-06.2006 · Cited by 142 · see citing works
Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent
Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142 · see citing works
APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians
Gureje, O., Ogunniyi, A., Baiyewu, O., Price, B., Unverzagt, F. W., Evans, R. M., Smith‐Gamble, V., Lane, K. A., Gao, S., Hall, K. S., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20694 · Cited by 139 · see citing works
The Interaction between Apolipoprotein E and Alzheimer's Amyloid β-Peptide Is Dependent on β-Peptide Conformation
Golabek, A. A., Soto, C. A., Vogel, T., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10602 · Cited by 137 · see citing works
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134 · see citing works
Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology: Miniperspective
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132 · see citing works
Absence of α-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice
Al-Wandi, A., Ninkina, N. N., Millership, S. J., Williamson, S. J. M., Jones, P. A., & Buchman, V. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.001 · Cited by 129 · see citing works
Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128 · see citing works
Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes
Rapp, A., Gmeiner, B. M. K., & Hüttinger, M. (2005) · Biochimie · doi:10.1016/j.biochi.2005.10.007 · Cited by 127 · see citing works
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · see citing works
Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00050-x · Cited by 118 · see citing works
Reduction of Brain β-Amyloid (Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments (APP-CTFs) and Aβ Clearance
Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., Yamashita, T., Uchiyama, Y., Rakugi, H., & Morishita, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102277 · Cited by 117 · see citing works
α-Synuclein Membrane Association Is Regulated by the Rab3a Recycling Machinery and Presynaptic Activity*
Chen, R. H., Wislet‐Gendebien, S., Samuel, F., Visanji, N. P., Zhang, G., Marsilio, D., Langman, T., Fraser, P. E., & Tandon, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439497 · Cited by 116 · see citing works
Multiple pathways of apolipoprotein E signaling in primary neurons
Hoe, H., Harris, D. C., & Rebeck, G. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.03007.x · Cited by 111 · see citing works
Exploring the Effect of Phyllanthus emblica L. on Cognitive Performance, Brain Antioxidant Markers and Acetylcholinesterase Activity in Rats: Promising Natural Gift for the Mitigation of Alzheimer's Disease
Uddin, M. S., Mamun, A. A., Hossain, M. S., Akter, F., Iqbal, M. A., & Asaduzzaman, M. (2016) · Annals of Neurosciences · doi:10.1159/000449482 · Cited by 109 · see citing works
Self-citation
Fatty acid incorporation is decreased in astrocytes cultured from α‐synuclein gene‐ablated mice
Castagnet, P. I., Golovko, M. Y., Barceló‐Coblijn, G., Nussbaum, R. L., & Murphy, E. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03247.x · Cited by 108 · see citing works
Apolipoprotein Receptor 2 and X11α/β Mediate Apolipoprotein E-Induced Endocytosis of Amyloid-β Precursor Protein and β-Secretase, Leading to Amyloid-β Production
He, X., Cooley, K., Chung, C. H. Y., Dashti, N., & Tang, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3993-06.2007 · Cited by 107 · see citing works
Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils
Hatters, D. M., Zhong, N., Rutenber, E., & Weisgraber, K. H. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.080 · Cited by 105 · see citing works
Concentration-Dependent Inhibitory Effects of Apolipoprotein E on Alzheimer's β-Amyloid Fibril Formation in Vitro
Naiki, H., Gejyo, F., & Nakakuki, K. (1997) · Biochemistry · doi:10.1021/bi9624705 · Cited by 103 · see citing works
Impact of Apolipoprotein E on Alzheimer’s Disease
Hauser, P. S., & Ryan, R. O. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990156 · Cited by 101 · see citing works
Role of α-synuclein in synaptic glutamate release
Gureviciene, I., Gurevicius, K., & Tanila, H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.06.016 · Cited by 100 · see citing works
Amyloid β40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice
Ji, Y., Permanne, B., Sigurdsson, E., Holtzman, D., & Wisniewski, T. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3105 · Cited by 96 · see citing works
Binding and uptake of Aβ1‐42 by primary human astrocytes in vitro
Nielsen, H. M., Veerhuis, R., Holmqvist, B., & Janciauskiene, S. (2009) · Glia · doi:10.1002/glia.20822 · Cited by 96 · see citing works
Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice
Hamanaka, H. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.353 · Cited by 96 · see citing works
High ability of apolipoprotein E4 to stabilize amyloid‐β peptide oligomers, the pathological entities responsible for Alzheimer's disease
Cerf, E., Gustot, A., Goormaghtigh, E., Ruysschaert, J., & Raussens, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-175976 · Cited by 94 · see citing works
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice
Skerrett, R., Pellegrino, M. P., Casali, B. T., Taraboanta, L., & Landreth, G. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.652008 · Cited by 89 · see citing works
Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration
Kuszczyk, M. A., Sanchez, S., Pankiewicz, J., Kim, J., Duszczyk, M., Guridi, M., Asuni, A. A., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.034 · Cited by 89 · see citing works
Apolipoprotein E modulates γ‐secretase cleavage of the amyloid precursor protein
Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A. F., Martin‐Rehrmann, M., Manelli, A., LaDu, M. J., Hyman, B. T., & Rebeck, G. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02581.x · Cited by 89 · see citing works
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels
Bekris, L. M., Millard, S. P., Galloway, N. M., Vuletic, S., Albers, J. J., Li, G., Galasko, D. R., DeCarli, C., Farlow, M. R., Clark, C. M., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13303 · Cited by 85 · see citing works
Cerebral clearance of human amyloid‐β peptide (1–40) across the blood–brain barrier is reduced by self‐aggregation and formation of low‐density lipoprotein receptor‐related protein‐1 ligand complexes
Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85 · see citing works
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphisms
Wahrle, S. E., Shah, A. R., Fagan, A. M., Smemo, S., Kauwe, J. S., Grupe, A., Hinrichs, A., Mayo, K., Jiang, H., Thal, L. J., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-7 · Cited by 84 · see citing works
γ-Secretase Catalyzes Sequential Cleavages of the AβPP Transmembrane Domain
Xu, X. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0957 · Cited by 83 · see citing works
Cathepsin D-mediated proteolysis of apolipoprotein E: Possible role in Alzheimer’s disease
Zhou, W., Scott, S. A., Shelton, S. B., & Crutcher, K. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.019 · Cited by 82 · see citing works
APOE-Mimetic Peptides Reduce Behavioral Deficits, Plaques and Tangles in Alzheimer’s Disease Transgenics
Vitek, M. P., Christensen, D. J., Wilcock, D. M., Davis, J., Nostrand, W. E. V., Li, F. Q., & Colton, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000334914 · Cited by 82 · see citing works
Obesity Accelerates Alzheimer-Related Pathology inAPOE4but notAPOE3Mice
Moser, V. A., & Pike, C. J. (2017) · eNeuro · doi:10.1523/eneuro.0077-17.2017 · Cited by 82 · see citing works
β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons
Beffert, U., Aumont, N., Dea, D., Lussier‐Cacan, S., Davignon, J., & Poirier, J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041458.x · Cited by 77 · see citing works
Apolipoprotein E4 domain interaction: Synaptic and cognitive deficits in mice
Zhong, N., Scearce-Levie, K. A., Ramaswamy, G., & Weisgraber, K. H. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.01.006 · Cited by 76 · see citing works
Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function.
Teter, B., Xu, P., Gilbert, J. R., Roses, A. D., Galasko, D., & Cole, G. M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10221 · Cited by 74 · see citing works
Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents
Osei-Hwedieh, D. O., Amar, M. J., Sviridov, D., & Remaley, A. T. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.003 · Cited by 71 · see citing works
Apolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase Cϵ
Sen, A., Alkon, D. L., & Nelson, T. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312710 · Cited by 69 · see citing works
Modulation of Aβ Deposition in APP Transgenic Mice by an Apolipoprotein E Null Background
IRIZARRY, M. C., REBECK, G. W., CHEUNG, B., BALES, K., PAUL, S. M., HOLZMAN, D., & HYMAN, B. T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06919.x · Cited by 66 · see citing works
Restoring synaptic plasticity and memory in mouse models of Alzheimer’s disease by PKR inhibition
Hwang, K., Bak, M. S., Kim, S. J., Rhee, S., & Lee, Y. (2017) · Molecular Brain · doi:10.1186/s13041-017-0338-3 · Cited by 65 · see citing works
Genetic studies of human apolipoproteins. X. The effect of the apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks.
Sepehrnia, B., Kamboh, M. I., Adams-Campbell, L. L., Bunker, C. H., Nwankwo, M. U., Majumder, P. P., & Ferrell, R. E. (1989) · PubMed · Cited by 65 · see citing works
Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran
Vaisi‐Raygani, A., Zahrai, M., Raygani, A. V., Doosti, M., Javadi, E., رضایی, م., & Pourmotabbed, T. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.073 · Cited by 64 · see citing works
APOE ε3/ε4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer’s disease diagnosis
Fukumoto, H., Ingelsson, M., Gårevik, N., Wahlund, L.-O., Nukina, N., Yaguchi, Y., Shibata, M., Hyman, B. T., Rebeck, G. W., & Irizarry, M. C. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00088-8 · Cited by 63 · see citing works
Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60 · see citing works
Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E
Weisgraber, K. H., Pitas, R. E., & Mahley, R. W. (1994) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(94)90212-7 · Cited by 58 · see citing works
Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 57 · see citing works
Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1
Tachibana, M., Shinohara, M., Yamazaki, Y., Liu, C., Rogers, J. T., Bu, G., & Kanekiyo, T. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.12.003 · Cited by 57 · see citing works
Native Complex Formation between Apolipoprotein E Isoforms and the Alzheimer's Disease Peptide Aβ
Chan, W., Fornwald, J. A., Brawner, M. E., & Wetzel, R. B. (1996) · Biochemistry · doi:10.1021/bi952852v · Cited by 56 · see citing works
Plasma Signaling Proteins in Persons at Genetic Risk for Alzheimer Disease
Ringman, J. M., Elashoff, D. A., Geschwind, D. H., Welsh, B. T., Gylys, K. H., Lee, C., Cummings, J. L., & Cole, G. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.277 · Cited by 55 · see citing works
Different mechanisms of apolipoprotein E isoform‐dependent modulation of prostaglandin E 2 production and triggering receptor expressed on myeloid cells 2 ( TREM2 ) expression after innate immune activation of microglia
Li, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54 · see citing works
Co-expression of β-amyloid precursor protein (βAPP) and apolipoprotein E in cell culture: analysis of βAPP processing
Biere, A. L., Ostaszewski, B., Zhao, H., Gillespie, S., Younkin, S. G., & Selkoe, D. J. (1995) · Neurobiology of Disease · doi:10.1006/nbdi.1995.0019 · Cited by 52 · see citing works
Neuroprotective Activity of Asparagus racemosus Linn. Against Ethanol- Induced Cognitive Impairment and Oxidative Stress in Rats Brain: Auspicious for Controlling the Risk of Alzheimer’s Disease
Uddin, M. S., & Asaduzzaman, M. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000245 · Cited by 51 · see citing works
Self-citation
The Apolipoprotein-E-Mimetic COG112 Protects Amyloid Precursor Protein Intracellular Domain-Overexpressing Animals from Alzheimer's Disease-Like Pathological Features
Ghosal, K., Stathopoulos, A. M., Thomas, D. G., Phenis, D., Vitek, M. P., & Pimplikar, S. W. (2012) · Neurodegenerative Diseases · doi:10.1159/000341299 · Cited by 50 · see citing works
Association between apolipoprotein E polymorphism and Alzheimer's disease in Koreans
Kim, K. W., Jhoo, J. H., Lee, K. U., Lee, D. Y., Lee, J. H., Youn, J. Y., Lee, B. J., Han, S. H., & Woo, J. I. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00867-8 · Cited by 50 · see citing works
In Vivo and In Vitro Effects of an Apolipoprotein E Mimetic Peptide on Amyloid-β Pathology
Handattu, S. P., Monroe, C. E., Nayyar, G., Palgunachari, M. N., Kadish, I., van Groen, T., Anantharamaiah, G. M., & Garber, D. W. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122377 · Cited by 49 · see citing works
Lack of Alpha-Synuclein Modulates Microglial Phenotype In Vitro
Austin, S. A., Rojanathammanee, L., Golovko, M. Y., Murphy, E. J., & Combs, C. K. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0439-9 · Cited by 49 · see citing works
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. D. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt135 · Cited by 49 · see citing works
Spectrum of Disease and Prescription Pattern for Outpatients with Neurological Disorders: An Empirical Pilot Study in Bangladesh
Uddin, M. S., Mamun, A. A., Asaduzzaman, M., Hosn, F., Sufian, M. A., Takeda, S., Herrera-Calderón, O., Abdel‐Daim, M. M., Uddin, G. M. S., Noor, M. A. A., et al. (2017) · Annals of Neurosciences · doi:10.1159/000481812 · Cited by 48 · see citing works
Self-citation
Allelic expression of APOE in human brain: Effects of epsilon status and promoter haplotypes
Bray, N. J., Jehu, L., Moskvina, V., Buxbaum, J. D., Dracheva, S., Haroutunian, V., Williams, J., Buckland, P. R., Owen, M. J., & O'Donovan, M. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh299 · Cited by 45 · see citing works
High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population
Achouri-Rassas, A., Khiari, H. M., Fredj, S. H., Sahnoun, S., Batti, H., Zakraoui, N. O., Cherif, A., Anane, N., Benali, N., Messaoud, T. B., et al. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0663-8 · Cited by 45 · see citing works
Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls
Pirttilä, T., Soininen, H., Heinonen, O., Lehtimäki, T., Bogdanovic, N., Paljärvi, L., Kosunen, O., Winblad, B., Riekkinen, P., Wisniewski, H. M., et al. (1996) · Brain Research · doi:10.1016/0006-8993(96)00183-7 · Cited by 42 · see citing works
Effects of different isoforms of apoE on aggregation of the α‐synuclein protein implicated in Parkinson’s disease
Emamzadeh, F. N., Aojula, H., McHugh, P. C., & Allsop, D. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.042 · Cited by 42 · see citing works
An ApoE-Aβ inhibition complex in Aβ fibril extension
Wood, S. J., Chan, W., & Wetzel, R. B. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90183-0 · Cited by 41 · see citing works
The apolipoprotein E 4 allele selectively increases the risk of frontotemporal lobar degeneration in males
Srinivasan, R. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.063966 · Cited by 39 · see citing works
ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer’s disease mouse model
Chan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016) · Scientific Reports · doi:10.1038/srep26119 · Cited by 39 · see citing works
Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease
Talwar, P., Sinha, J., Grover, S., Agarwal, R., Kushwaha, S. S., Srivastava, M. V. P., & Kukreti, R. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.12.004 · Cited by 37 · see citing works
Neurochemistry of Neurochemicals: Messengers of Brain Functions
Uddin, M. S., Mamun, A. A., Kabir, M. T., Nasrullah, M., Wahid, F., Begum, M. M., Labu, Z. K., Rahman, M. S., Islam, M. T., Amran, M. S., et al. (2018) · Journal of Intellectual Disability - Diagnosis and Treatment · doi:10.6000/2292-2598.2017.05.04.6 · Cited by 36 · see citing works
Self-citation
The Impact of a Novel Apolipoprotein E and Amyloid-β Protein Precursor-Interacting Protein on the Production of Amyloid-β
Hopkins, P. C. R., Sáinz‐Fuertes, R., & Lovestone, S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102115 · Cited by 35 · see citing works
ApoE mimetic peptide decreases Aβ production in vitro and in vivo
Minami, S. S., Cordova, A., Cirrito, J. R., Tesoriero, J. A., Babus, L. W., Davis, G. C., Dakshanamurthy, S., Turner, R. S., Pak, D. T., Rebeck, G. W., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-16 · Cited by 34 · see citing works
APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice
Pankiewicz, J. E., Baquero-Buitrago, J., Sanchez, S., Lopez-Contreras, J., Kim, J., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0156-1 · Cited by 34 · cited 1× · see citing works
“APOE genotype and immunotherapy ▪ Aids to forecast clinical consequence for Aβ-linked or other treatments Aβ immunotherapy [169, 170] Mol Neurobiol”
Background
An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo
Luz, I., Liraz, O., & M. Michaelson, D. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160404120817 · Cited by 33 · see citing works
Apolipoprotein E polymorphism in German patients with frontotemporal degeneration
Riemenschneider, M. J. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.5.639 · Cited by 31 · see citing works
Apolipoprotein E Polymorphism in Elderly Chilean People with Alzheimer’s Disease
Quiroga, P. M., Calvo, C., Cecilia Albala, B., Urquidi, J. A., Santos, J. L., Pérez, H., & Gonzalo Klaassen, P. (1998) · Neuroepidemiology · doi:10.1159/000026195 · Cited by 30 · see citing works
Apolipoprotein E alters the processing of the β-amyloid precursor protein in APPV717F transgenic mice
Dodart, J.-C., Bales, K. R., Johnstone, E. M., Little, S. P., & Paul, S. M. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03437-6 · Cited by 30 · see citing works
Apolipoprotein E4 Impairs in vivo Hippocampal Long-Term Synaptic Plasticity by Reducing the Phosphorylation of CaMKIIα and CREB
Qiao, F., Gao, X., Li, Y., Cai, H.-Y., & Qi, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140375 · Cited by 27 · see citing works
Aβ20–29 peptide blocking apoE/Aβ interaction reduces full-length Aβ42/40 fibril formation and cytotoxicity in vitro
Hao, J., Zhang, W., Zhang, P., Liu, R., Liu, L., Lei, G., Su, C., Miao, J., & Li, Z. (2010) · Neuropeptides · doi:10.1016/j.npep.2010.03.001 · Cited by 26 · see citing works
Untitled work
(2002) · PubMed · Cited by 24 · see citing works
Genomic Discoveries and Personalized Medicine in Neurological Diseases
Zhang, L., & Hong, H. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7040542 · Cited by 20 · see citing works
The effects of apolipoprotein E genotype, α‐synuclein deficiency, and sex on brain synaptic and Alzheimer's disease–related pathology
Bar, R., Boehm‐Cagan, A., Luz, I., Kleper-Wall, Y., & Michaelson, D. M. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.08.003 · Cited by 19 · see citing works
Searching the Linkage between High Fat Diet and Alzheimer′s Disease: A Debatable Proof Stand for Ketogenic Diet to Alleviate Symptoms of Alzheimer′s Patient with APOE ε4 Allele
Uddin, M. S., & Haque, A. (2016) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000397 · Cited by 18 · see citing works
Self-citation
APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease
Hohman, T. J., Dumitrescu, L. C., Oksol, A., Wagener, M. A., Gifford, K. A., Jefferson, A. L., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188501 · Cited by 14 · see citing works
APOE genotype and Alzheimer’s immunotherapy
Pankiewicz, J. E., & Sadowski, M. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17990 · Cited by 11 · see citing works
Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson’s Disease
Lu, S., & Shaffery, J. P. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000255 · Cited by 4 · see citing works

Flagged first, then by citations

Sorted by citations

Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003 · see citing works
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516 · see citing works
“ApoE4, the most potent risk factor for the pathogenesis of LOAD, modulates neuroinflammatory response and glial activation [138].”
Background
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 438 · see citing works
Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease
Zaplatić, E., Bule, M. H., Shah, S. Z. A., Uddin, M. S., & Niaz, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.055 · Cited by 298 · see citing works
Self-citation
Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics
Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 283 · see citing works
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217 · see citing works
Self-citation
Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer’s disease
Li, Y., Zhang, J., Wan, J., Liu, A., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110887 · Cited by 212 · see citing works
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183 · see citing works
Circadian and sleep dysfunction in Alzheimer’s disease
Uddin, M. S., Tewari, D., Mamun, A. A., Kabir, M. T., Niaz, K., Wahed, M. I. I., Barreto, G. E., & Ashraf, G. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101046 · Cited by 180 · see citing works
Self-citation
Neuroinflammation: A Potential Risk for Dementia
Ahmad, M. A., Kareem, O., Khushtar, M., Akbar, M., Haque, M. R., Iqubal, A., Haider, M. F., Pottoo, F. H., Abdulla, F. S., Al-Haidar, M. B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020616 · Cited by 163 · see citing works
Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Mathew, G. E., Uddin, M. S., Kim, H., & Mathew, B. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13132 · Cited by 157 · see citing works
Self-citation
Estrogen Signaling in Alzheimer’s Disease: Molecular Insights and Therapeutic Targets for Alzheimer’s Dementia
Uddin, M. S., Rahman, M. M., Jakaria, M., Rahman, M. S., Hossain, M. S., Islam, A., Ahmed, M., Mathew, B., Omar, U. M., Barreto, G. E., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01911-8 · Cited by 156 · see citing works
Self-citation
Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease
Arbo, B. D., André‐Miral, C., Nasre‐Nasser, R. G., Schimith, L. E., dos Santos, M. G., da Costa-Silva, D. G., Muccillo-Baisch, A. L., & Hort, M. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00103 · Cited by 156 · see citing works
Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders
Uddin, M. S., Mamun, A. A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M. A., Mathew, B., Abdel-Daim, M. M., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135624 · Cited by 154 · see citing works
Self-citation
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152 · see citing works
Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis
Uddin, M. S., Mamun, A. A., Labu, Z. K., Hidalgo‐Lanussa, O., Barreto, G. E., & Ashraf, G. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27588 · Cited by 140 · see citing works
Self-citation
Melatonin in Alzheimer’s Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer’s Neuropathology
Hossain, M. F., Uddin, M. S., Uddin, G. M. S., Sumsuzzman, D. M., Islam, M. S., Barreto, G. E., Mathew, B., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01660-3 · Cited by 135 · see citing works
Self-citation
Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo‐Sánchez, E., Ashraf, G. M., et al. (2020) · Molecules · doi:10.3390/molecules25061267 · Cited by 134 · see citing works
Self-citation
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Unnikrishnan, M. K., Uddin, M. S., Mathew, G. E., Pratap, R., Marathakam, A., & Mathew, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.018 · Cited by 124 · see citing works
Self-citation
NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Kabir, M. T., Sufian, M. A., Uddin, M. S., Begum, M. M., Akhter, S., Islam, A., Mathew, B., Islam, M. S., Amran, M. S., & Ashraf, G. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191011102444 · Cited by 120 · see citing works
Self-citation
Emerging Signal Regulating Potential of Genistein Against Alzheimer’s Disease: A Promising Molecule of Interest
Uddin, M. S., & Kabir, M. T. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00197 · Cited by 119 · see citing works
Self-citation
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Kabir, M. T., Uddin, M. S., Begum, M. M., Thangapandiyan, S., Rahman, M. S., Aleya, L., Mathew, B., Ahmed, M., Barreto, G. E., & Ashraf, G. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191008103141 · Cited by 119 · see citing works
Self-citation
Pharmacological approaches to mitigate neuroinflammation in Alzheimer’s disease
Uddin, M. S., Kabir, M. T., Mamun, A. A., Barreto, G. E., Rashid, M., Perveen, A., & Ashraf, G. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106479 · Cited by 115 · see citing works
Self-citation
Nootropic and Anti-Alzheimer’s Actions of Medicinal Plants: Molecular Insight into Therapeutic Potential to Alleviate Alzheimer’s Neuropathology
Uddin, M. S., Mamun, A. A., Kabir, M. T., Jakaria, M., Mathew, B., Barreto, G. E., & Ashraf, G. M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1420-2 · Cited by 110 · see citing works
Self-citation
Thyroid hormone: sex-dependent role in nervous system regulation and disease
Baksi, S., & Pradhan, A. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00367-2 · Cited by 108 · see citing works
Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Ramachandran, A. K., Das, S., Joseph, A., Shenoy, G. G., Alex, A. T., & Mudgal, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200807130637 · Cited by 94 · see citing works
Exploring the multimodal role of phytochemicals in the modulation of cellular signaling pathways to combat age-related neurodegeneration
Uddin, M. S., Hossain, M. F., Mamun, A. A., Shah, M. A., Hasana, S., Bulbul, I. J., Sarwar, M. S., Mansouri, R. A., Ashraf, G. M., Rauf, A., et al. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138313 · Cited by 88 · see citing works
Self-citation
Neuroprotective effects of verbascoside against Alzheimer’s disease via the relief of endoplasmic reticulum stress in Aβ-exposed U251 cells and APP/PS1 mice
Wang, C., Cai, X., Wang, R., Zhai, S., Zhang, Y., Hu, W., Zhang, Y., & Wang, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01976-1 · Cited by 87 · see citing works
Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mathew, B., & Aleya, L. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134836 · Cited by 83 · see citing works
Self-citation
Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank
Zhang, X., Hu, W., Wang, Y., Wang, W., Liao, H., Zhang, X., Kiburg, K., Shang, X., Bulloch, G., Huang, Y., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02449-3 · Cited by 83 · see citing works
Royal Jelly as an Intelligent Anti-Aging Agent—A Focus on Cognitive Aging and Alzheimer’s Disease: A Review
Ali, A. M., & Kunugi, H. (2020) · Antioxidants · doi:10.3390/antiox9100937 · Cited by 82 · see citing works
Insulin resistance as the molecular link between diabetes and Alzheimer's disease
Abdalla, M. M. I. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1430 · Cited by 82 · see citing works
Directed acyclic graphs and causal thinking in clinical risk prediction modeling
Piccininni, M., Konigorski, S., Rohmann, J. L., & Kurth, T. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01058-z · Cited by 79 · see citing works
Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
Kumar, R., Harilal, S., Gupta, S. V., Jose, J., Parambi, D. G. T., Uddin, M. S., Shah, M. A., & Mathew, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111602 · Cited by 75 · see citing works
Self-citation
Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone‐based benzenesulfonamides
Tugrak, M., Gul, H. I., Demir, Y., Levent, S., & Gülçın, İ. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000375 · Cited by 74 · see citing works
Curcumin, inflammation, and neurological disorders: How are they linked?
Garodia, P., Hegde, M., Kunnumakkara, A. B., & Aggarwal, B. B. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100968 · Cited by 73 · see citing works
Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
Klinger, D., Hill, B. L., Barda, N., Halperin, E., Gofrit, O. N., Greenblatt, C. L., Rappoport, N., Linial, M., & Bercovier, H. (2021) · Vaccines · doi:10.3390/vaccines9050491 · Cited by 71 · see citing works
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 68 · see citing works
Self-citation
Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease
Uddin, M. S., Rahman, M. A., Kabir, M. T., Behl, T., Mathew, B., Perveen, A., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · IUBMB Life · doi:10.1002/iub.2324 · Cited by 66 · see citing works
Self-citation
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 65 · see citing works
Self-citation
Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Kabir, M. T., Khanum, S., Sarwar, M. S., Mathew, B., Rauf, A., Ahmed, M., & Ashraf, G. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00185-1 · Cited by 63 · see citing works
Self-citation
Genetic testing in dementia — utility and clinical strategies
Koriath, C., Kenny, J., Ryan, N. S., Rohrer, J. D., Schott, J. M., Houlden, H., Fox, N. C., Tabrizi, S. J., & Mead, S. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00416-1 · Cited by 59 · see citing works
Emerging Proof of Protein Misfolding and Interactions in Multifactorial Alzheimer's Disease
Uddin, M. S., Mamun, A. A., Rahman, M. A., Behl, T., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200601161703 · Cited by 59 · see citing works
Self-citation
The role of DHCR24 in the pathogenesis of AD: re-cognition of the relationship between cholesterol and AD pathogenesis
Bai, X., Mai, M., Yao, K., Zhang, M., Huang, Y. M., Zhang, W., Guo, X., Xu, Y., Zhang, Y., Qurban, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01338-3 · Cited by 56 · see citing works
Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals
Schultz, N., Byman, E., Bank, T. N. B., & Wennström, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190868 · Cited by 55 · see citing works
ApoE4 (Δ272–299) induces mitochondrial‐associated membrane formation and mitochondrial impairment by enhancing GRP75-modulated mitochondrial calcium overload in neuron
Liang, T., Hang, W., Chen, J., Wu, Y., Wen, B., Xu, K., Ding, B., & Chen, J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00563-y · Cited by 54 · see citing works
ApoE4 attenuates autophagy via FoxO3a repression in the brain
Sohn, H.-Y., Kim, S.-I., Park, J.-Y., Park, S.-H., Koh, Y. H., Kim, J., & Jo, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-97117-6 · Cited by 54 · see citing works
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 53 · see citing works
Self-citation
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 53 · see citing works
Self-citation
Curcumin Reduces Cognitive Deficits by Inhibiting Neuroinflammation through the Endoplasmic Reticulum Stress Pathway in Apolipoprotein E4 Transgenic Mice
Kou, J., Wang, M., Shi, J., Zhang, H., Pu, X., Song, S., Yang, C., Yan, Y., Döring, Y., Xie, X., et al. (2021) · ACS Omega · doi:10.1021/acsomega.0c04810 · Cited by 52 · see citing works
6‴-Feruloylspinosin alleviated beta-amyloid induced toxicity by promoting mitophagy in Caenorhabditis elegans (GMC101) and PC12 cells
Yang, T., Zhao, X., Zhang, Y., Xie, J., & Zhou, A. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.136953 · Cited by 51 · see citing works
Oxidative Stress in Alzheimer’s Disease: Molecular Hallmarks of Underlying Vulnerability
Uddin, M. S., & Kabir, M. T. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_5 · Cited by 49 · see citing works
Self-citation
Analyzing the chance of developing dementia among geriatric people: a cross‐sectional pilot study in Bangladesh
Uddin, M. S., Mamun, A. A., Takeda, S., Sarwar, M. S., & Begum, M. M. (2018) · Psychogeriatrics · doi:10.1111/psyg.12368 · Cited by 48 · see citing works
Self-citation
Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation
Fan, X., Li, J., Deng, X., Lu, Y., Feng, Y., Ma, S., Wen, H., Zhao, Q., Tan, W., Shi, T., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112217 · Cited by 48 · see citing works
Pericytes Across the Lifetime in the Central Nervous System
Bennett, H. C., & Kim, Y. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.627291 · Cited by 47 · see citing works
The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease
Raulin, A.-C., Kraft, L., Al-Hilaly, Y. K., Xue, W.-F., McGeehan, J. E., Atack, J. R., & Serpell, L. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.019 · Cited by 47 · see citing works
Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer’s Disease
Chaudhari, V., Bagwe‐Parab, S., Buttar, H. S., Gupta, S., Vora, A., & Kaur, G. (2023) · Neurotoxicity Research · doi:10.1007/s12640-023-00634-7 · Cited by 46 · see citing works
The Role of Acyl-CoA β-Oxidation in Brain Metabolism and Neurodegenerative Diseases
Szrok-Jurga, S., Turyn, J., Hebanowska, A., Świerczyński, J., Czumaj, A., Śledziński, T., & Stelmańska, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813977 · Cited by 46 · see citing works
TV 3326 for Alzheimer’s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer’s-like neuropathology
Uddin, M. S., Kabir, M. T., Rahman, M. M., Mathew, B., Shah, M. A., & Ashraf, G. M. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13244 · Cited by 44 · see citing works
Self-citation
Ethinylestradiol (EE2) residues from birth control pills impair nervous system development and swimming behavior of zebrafish larvae
Nasri, A., Mezni, A., Lafon, P., Wahbi, A., Cubedo, N., Clair, P., Harrath, A. H., Beyrem, H., Rossel, M., & Perrier, V. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145272 · Cited by 44 · see citing works
Insights on benzodiazepines' potential in Alzheimer's disease
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alsayegh, A. A., Abusudah, W. F., Almohmadi, N. H., Eldahshan, O. A., Ahmed, E., & Batiha, G. E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121532 · Cited by 44 · see citing works
Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins
Chamani, S., Bianconi, V., Tasbandi, A., Pirro, M., Barreto, G. E., Jamialahmadi, T., & Sahebkar, A. (2020) · Mediators of Inflammation · doi:10.1155/2020/3267172 · Cited by 44 · see citing works
Self-citation
Possible Neuropathology of Sleep Disturbance Linking to Alzheimer’s Disease: Astrocytic and Microglial Roles
Xiao, S., Liu, Y.-J., Wang, L., Sha, Z., Che, X., Yu, Z., & Lee, S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.875138 · Cited by 40 · see citing works
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41 · see citing works
Plasma amyloid beta levels and platelet mitochondrial respiration in patients with Alzheimer's disease
Fišar, Z., Jirák, R., Zvěřová, M., Setnička, V., Habartová, L., Hroudová, J., Vaníčková, Z., & Raboch, J. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.003 · Cited by 38 · see citing works
Application of yeast to studying amyloid and prion diseases
Chernoff, Y. O., Grizel, A. V., Rubel, A. A., Zelinsky, A. А., Chandramowlishwaran, P., & Chernova, T. A. (2020) · Advances in genetics · doi:10.1016/bs.adgen.2020.01.002 · Cited by 37 · see citing works
RETRACTION OF: A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition
Sawmiller, D. R., Habib, A., Hou, H., Mori, T., Fan, A., Tian, J., Jin, Z., Giunta, B. N., Sanberg, P. R., Mattson, M. P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.026 · Cited by 37 · see citing works
Retracted
The association of APOE genotype with COVID-19 disease severity
Lord, J. S., Rezaiezadeh, J. S., Yekaninejad, M. S., & Izadi, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-17262-4 · Cited by 35 · see citing works
DHCR24 reverses Alzheimer’s disease-related pathology and cognitive impairment via increasing hippocampal cholesterol levels in 5xFAD mice
Zhang, W.-B., Huang, Y. M., Guo, X., Zhang, M.-Q., Yuan, X.-S., & Zu, H. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01593-y · Cited by 34 · see citing works
Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer’s disease
Javed, B., Javed, A., Kow, C. S., & Hasan, S. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2214316 · Cited by 33 · see citing works
Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfunction Via Aquaporin-4 Polarization
Sun, H., Cao, Q., He, X., Du, X., Jiang, X., Wu, T., & Xiao, M. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04992-5 · Cited by 33 · see citing works
Clemastine attenuates AD-like pathology in an AD model mouse via enhancing mTOR-mediated autophagy
Li, Z., Chen, L., Zhao, X., Chen, H., Sun, Y., Lu, M., Wang, Z.-T., Chen, M., Li, L., Huang, W., et al. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113742 · Cited by 33 · see citing works
Advanced nano delivery system for stem cell therapy for Alzheimer's disease
Pan, Y., Li, L., Cao, N., Liao, J., Chen, H., & Zhang, M. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122852 · Cited by 32 · see citing works
Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 31 · see citing works
Self-citation
Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
Nemergut, M., Marques, S. M., Uhrik, L., Vanova, T., Nezvedova, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00620-9 · Cited by 30 · see citing works
Acute aflatoxin B1-induced hepatic and cardiac oxidative damage in rats: Ameliorative effects of morin
Altyar, A. E., Kensara, O. A., Sayed, A. A., Aleya, L., Almutairi, M. H., Zaazouee, M. S., Elshanbary, A. A., El-Demerdash, F. M., & Abdel‐Daim, M. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21837 · Cited by 30 · see citing works
Self-citation
Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
Lu, J., Wang, X., Wan, L., Fu, J., Huo, Y., Zhao, Y., & Guo, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00934 · Cited by 29 · see citing works
Disrupted Excitation-Inhibition Balance in Cognitively Normal Individuals at Risk of Alzheimer’s Disease
Fortel, I., Zhan, L., Ajilore, O., Wu, Y., Mackin, R. S., & Leow, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230035 · Cited by 27 · see citing works
A whole-process interpretable and multi-modal deep reinforcement learning for diagnosis and analysis of Alzheimer’s disease ∗
Zhang, Q., Du, Q., & Liu, G. (2021) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac37cc · Cited by 27 · see citing works
Emerging Therapeutic Promise of Ketogenic Diet to Attenuate Neuropathological Alterations in Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Barreto, G. E., BUNGAU, S. G., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02065-3 · Cited by 27 · see citing works
Self-citation
Prevalence, deaths and disability-adjusted life years due to Alzheimer’s disease and other dementias in Middle East and North Africa, 1990–2021
Amiri, F., Safiri, S., Shamekh, A., Ebrahimi, A. A., Sullman, M. J. M., & Kolahi, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-89899-w · Cited by 26 · see citing works
Breviscapine exerts neuroprotective effects through multiple mechanisms in APP/PS1 transgenic mice
Zhu, L., Zhang, X.-B., Gu, J.-H., Zeng, Y.-Q., & Li, J. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03698-7 · Cited by 26 · see citing works
The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis
Naseri, A., Baghernezhad, K., Sahebari, S. S., Alhoseini, S. A., Gholipour-khalili, E., Zafarani, F., & Talebi, M. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104011 · Cited by 26 · see citing works
Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction – A systematic review and meta-analysis
Rademacher, T.-D., Meuth, S. G., Wiendl, H., Johnen, A., & Landmeyer, N. C. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105035 · Cited by 26 · see citing works
Intranasal galantamine/chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect
Kandil, L. S., Farid, R. M., El-Gamal, S. S., & Hanafy, A. S. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2021.1934861 · Cited by 24 · see citing works
Research progress of the CXCR4 mechanism in Alzheimer's disease
Wang, Q., Fang, C., Huang, X., & Xue, L. (2022) · Ibrain · doi:10.1002/ibra.12026 · Cited by 24 · see citing works
Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer’s disease
Xiong, X., Hu, T., Yin, Z., Zhang, Y., Chen, F., & Lei, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.944283 · Cited by 24 · see citing works
Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer’s Disease
Faraji, P., Kühn, H., & Ahmadian, S. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02224-4 · Cited by 23 · see citing works
Molecular hydrogen may activate the transcription factor Nrf2 to alleviate oxidative stress through the hydrogen-targeted porphyrin
http://www.antpublisher.com/index.php/APT/article/view/566/692, & Ohta, S. (2023) · Aging Pathobiology and Therapeutics · doi:10.31491/apt.2023.03.104 · Cited by 23 · see citing works
Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Rahman, M. H., Alim, M. A., Rahman, M. M., Khatkar, A., Mamun, A. A., Rauf, A., Mathew, B., & Ashraf, G. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406075044 · Cited by 22 · see citing works
Self-citation
Amyloid Beta Peptide Is an Endogenous Negative Allosteric Modulator of Leptin Receptor
Cecon, E., Lhomme, T., Maurice, T., Luka, M., Chen, M., Silva, A. J., Wauman, J., Zabeau, L., Tavernier, J. H., Prévot, V., et al. (2020) · Neuroendocrinology · doi:10.1159/000508105 · Cited by 20 · see citing works
Microarray Profile of Long Noncoding RNA and Messenger RNA Expression in a Model of Alzheimer’s Disease
Wang, L., Zeng, L., Jiang, H., Li, Z., & Liu, R. (2020) · Life · doi:10.3390/life10050064 · Cited by 20 · see citing works
Apoptosis in hippocampal tissue induced by oxidative stress in testosterone deprived male rats
Muthu, S., & Prakash, S. (2020) · The Aging Male · doi:10.1080/13685538.2021.1892625 · Cited by 20 · see citing works
The Conceivable Role of Metabolic Syndrome in the Pathogenesis of Alzheimer’s Disease: Cellular and Subcellular Alterations in Underpinning a Tale of Two
Alzarea, E. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Beshay, O. N., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08832-6 · Cited by 19 · see citing works
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
Lennol, M. P., Sánchez-Domínguez, I., Cuchillo‐Ibáñez, I., Camporesi, E., Brinkmalm, G., Alcolea, D. A., Fortea, J., Lleó, A., Sòria, G., Aguado, F., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01108-2 · Cited by 19 · see citing works
Neurodegenerative diseases and brain delivery of therapeutics: Bridging the gap using dendrimers
Kaur, A., Singh, N., Kaur, H., Kakoty, V., Sharma, D. S., Khursheed, R., Babu, M. R., Harish, V., Gupta, G., Gulati, M., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104868 · Cited by 19 · see citing works
Positive association of a Sirt1 variant and parameters of oxidative stress on Alzheimer’s disease
Camporez, D., Belcavello, L., Almeida, J. F. F., Sena, G. G. S., Pimassoni, L. H. S., Morelato, R. L., Batitucci, M. D. C. P., & Paula, F. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04704-y · Cited by 19 · see citing works
Vanillic acid attenuates amyloid β1-40-induced long-term potentiation deficit in male rats: an in vivo investigation
Ahmadi, N., Mirazi, N., Komaki‬, A., Safari, S., & Hosseini, A. (2021) · Neurological Research · doi:10.1080/01616412.2021.1893565 · Cited by 19 · see citing works
New insight on the potential detrimental effect of metabolic syndrome on the Alzheimer disease neuropathology: Mechanistic role
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Bahaa, M. M., Al-Ibrahim, F., & Batiha, G. E. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70118 · Cited by 17 · see citing works
Sex and APOE ɛ4 modify the effect of cardiovascular risk on tau in cognitively normal older adults
Tsiknia, A. A., Reas, E. T., Bangen, K. J., Sundermann, E. E., McEvoy, L. K., Brewer, J. B., Edland, S. D., Banks, S. J., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac035 · Cited by 17 · see citing works

APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics
Husain, M. A., Laurent, B., & Plourde, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.630502 · Cited by 353 · see citing works
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · see citing works
Role of Apolipoprotein E in Alzheimer's Disease Pathogenesis, Prognosis and Treatment
Reiss, A. B., Housny, M., Gulkarov, S., Hossain, T., Locke, B., Srivastava, A., Pinkhasov, A., Gomolin, I. H., Wısnıewskı, T., & Leon, J. D. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436189.179 · Cited by 11 · see citing works
Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches
Sun, Y.-Y., Wang, Z., & Huang, H. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01365-1 · Cited by 95 · see citing works
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · see citing works

Authors: Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M.
Affiliations: Southeast University (BD)
BRAC University (BD)
Pontificia Universidad Javeriana (CO)
King Abdulaziz University (SA)
Corresponding author: Uddin, Md. Sahab
Ashraf, Ghulam Md
ORCID: Uddin, Md. Sahab
Kabir, Md. Tanvir
Barreto, George E.
Ashraf, Ghulam Md
Venue: Molecular Neurobiology
Publisher: Springer Science and Business Media LLC
Published: 2018-07-21
Volume: 56
Issue: 4
Pages: 2450-2465
ISSN: 0893-7648 (ISSN-L)
1559-1182
DOI: 10.1007/s12035-018-1237-z
OpenAlex: W2883974615
Cited by: 212
References: 175
Citations by year: 2026: 9 · 2025: 25 · 2024: 15 · 2023: 34 · 2022: 34 · 2021: 23 · 2020: 49 · 2019: 20 · 2018: 3
FWCI: 3.12
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Molecular Neurobiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: apolipoprotein E, APOE ε4, Alzheimer's disease, amyloid-beta, tau pathology, APOE isoforms, neuroinflammation, lipid metabolism, synaptic plasticity, synucleinopathies, neurodegeneration
MeSH terms: Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Humans, Risk Factors, Genetic Predisposition to Disease, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

APOE and Alzheimer’s Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer’s Pathogenesis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks